Introduce your patients to the only medical probiotic

Pendulum has developed a unique medical probiotic that helps in the management of Type 2 diabetes.

Containing Akkermansia muciniphila and a blend of four other high-potency bacteria strains, Pendulum Glucose Control was shown in a clinical trial to help manage Type 2 diabetes in people who were also taking metformin.

A medical food is a substance consumed internally or by mouth - either eaten or swallowed, under the supervision of a physician which is intended for the specific dietary management of a disease or condition. This sets Pendulum Glucose Control apart from both drugs and standard probiotics.
A1C Reduction 1
-0.6%
Post Prandial Glucose spike reduction 2
-32.5%

Our clinical trial.

We conducted a double-blind, placebo-controlled nutrition study that demonstrated:

• Pendulum Glucose Control’s safety

• Pendulum Glucose Control statistically and clinically significant impact on A1C and post-meal blood-glucose spikes

Clinical trial included participants taking metformin, compared to placebo. 1. Regarding the decreased A1C level, there was a reduction in mean A1C compared to placebo. 2. Regarding the Post Prandial Glucose Spike Reduction, the observed reduction in glucose AUC would be expected to increase the time spent within the healthy glucose range (TIR70-180) during continuous glucose monitoring.  Increases in TIR70-180 strongly correlate to both reductions in A1C and reduction in risk for complications in T2D patients (see details here).

Read now

Mechanism of Action

Pendulum Glucose Control is a patented formulation of five anaerobic probiotics strains, as well as the prebiotic inulin—which provides the initial food source for the 5 probiotics.

This unique synbiotic helps restore the body’s natural capabilities to produce butyrate, which helps meet the unique dietary needs of people with Type 2 diabetes.

Butyrate is the primary energy source for colonocytes. Butyrate binds to specific receptors within the gut mucosa and stimulates the release of glucagon-like peptide-1 (GLP-1), which is an incretin hormone. Glucagon-like peptide-1 is deficient in people with impared glucose tolerance and Type 2 diabetes, which contributes to hyperglycemia.

In  people who are not living with Type 2 diabetes, GLP-1 

  • Promotes satiety and reduces appetite
  • Enhances insulin secretion in the beta cells
  • Reduces glucose output from the liver
  • Helps regulate gastric emptying



Pendulum Glucose Control works by:

  • Relying on the body’s ability to produce short-chain fatty acids—including butyrate
  • Restoring the mucin lining of the gut

    Our studies

    Medical Food Assessment Using a Smartphone App with Continuous Glucose Monitoring Sensors: Proof-of-Concept Study

    Read Study

    Improvements to Postprandial Glucose Control in Subjects with Type 2 Diabetes (T2D)

    Read Study

    Review: Butyrate-producing human gut symbiont, Clostridium butyricum, and its role in health and disease

    Read Study

    Pendulum Glucose Control is more than a probiotic, it’s a medical food

    Medical foods are a special product category distinct from pharmaceuticals, conventional foods, and supplements. 

    As defined by Congress in the Orphan Drug Act, the term medical food, is: A food which is formulated to be consumed or administered enterally under the supervision of a physician and which is intended for the specific dietary management of a disease or condition for which distinctive nutritional requirements based on recognized scientific principles, are established by medical evaluation.

    In other words, Pendulum Glucose Control is uniquely designed to help with the dietary management of Type 2 diabetes.

    Have a question or want more info about Pendulum products?

    Drop us a line at hcpinfo@pendulumlife.com.

    Science starts with collaboration

    From Ph.D.s to MDs to RDs, we’re surrounded by smarts.

    We’ve partnered with top doctors, researchers, and scientists from pretty impressive institutions—like Stanford, Johns Hopkins, UCLA, Mayo Clinic, and the American Diabetes Association.

    Our medical research team is led by Chief Medical Officer Orville Kolterman, MD. Dr. Kolterman is a diabetes expert and previous Chief Medical Officer at Amylin Pharmaceuticals, where he brought four diabetes drugs from early-stage development through trials to market.

    Together with Dr. Kolterman, we work with leading diabetes professionals to ensure our products deliver results and meet the highest standards of efficacy and safety.

    John Buse, MD John Buse, MD

    John Buse, MD

    Chair, Division of Endocrinology
    University of North Carolina School of Medicine

    Purna Kashyap, MBBS Purna Kashyap, MBBS

    Purna Kashyap, MBBS

    Associate Professor, Medicine
    Mayo Clinic

    Davida Krueger, NP Davida Krueger, NP

    Davida Krueger, NP

    Nurse Practitioner
    Henry Ford Health System

    Chair
    American Diabetes Association (ADA) Research Foundation

    Emeran Mayer, MD Emeran Mayer, MD

    Emeran Mayer, MD

    Director, Oppenheimer Center For Neurobiology of Stress and Resilience

    Professor, Department of Medicine
    UCLA

    Jay Pasricha, MD Jay Pasricha, MD

    Jay Pasricha, MD

    Director, Neurogastroenterology Vice Chair, Medicine Innovation and Commercialization
    Johns Hopkins University

    Anne Peters, MD Anne Peters, MD

    Anne Peters, MD

    Director, Clinical Diabetes
    University of Southern California Private Practice

    Robert Ratner, MD Robert Ratner, MD

    Robert Ratner, MD

    Chief Medical Officer
    Virta Health

    Fmr Chief Scientific & Medical Officer
    American Diabetes Association

    Carol Wysham, MD Carol Wysham, MD

    Carol Wysham, MD

    Professor
    University of Washington

    Practitioner
    Rockwood Multicare Center for Diabetes

    Chris Mason, Ph.D. Chris Mason, Ph.D.

    Chris Mason, Ph.D.

    Associate Professor, Integrative Functional Genomics, Clinical Genetics and Synthetic Biology
    Cornell University

    Eric Schadt, Ph.D. Eric Schadt, Ph.D.

    Eric Schadt, Ph.D.

    CEO
    Sema4

    Dean Precision Medicine
    Mount Sinai Medicine

    Alfred Spormann, Ph.D. Alfred Spormann, Ph.D.

    Alfred Spormann, Ph.D.

    Professor, Civil and Environmental Engineering
    Stanford University

    Peter Turnbaugh, Ph.D Peter Turnbaugh, Ph.D

    Peter Turnbaugh, Ph.D

    Assistant Professor, Department of Microbiology and Immunology
    UCSF

    Dietrich Stephan, Ph.D. Dietrich Stephan, Ph.D.

    Dietrich Stephan, Ph.D.

    CEO
    Neubase Therapeutics

    Chair, Department of Human Genetics
    University of Pittsburgh

    Want to become a Pendulum partner?

    We’d love to share how our partnership program works.

    Blog Posts
    What Blend of Probiotics and a Prebiotic is Inside Pendulum Glucose Control?
    What Blend of Probiotics and a Prebiotic is Inside Pendulum Glucose Control?